Meeting Abstract RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- RLS-0071 Inhibits Acute Lung Injury in a Novel 2-Hit Model
- ROBUST III: Interim results of a randomized trial of the optilume drug coated balloon for anterior urethral strictures
- Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement
- Role of corticotropin releasing hormone (CRH) in footshock stress-induced alterations in sleep
- Role of COX-2 in Decidualization of Endometrial Stromal Cells
- Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance
- Role of E3 ubiquitin ligase GRAIL in B cell activation and tolerance
- Role of endoplasmic reticulum stress and thrombosis in type 2 diabetes-induced vascular dysfunction
- Role of peripheral immune response in regulating chemokine and pro-inflammatory cytokine profiles during acute viral encephalitis
- Role of plasma octreotide and chromogranin A (CGA) level in the management of neuroendocrine tumors (NET)
- Role of Stromal Interaction Molecule 1 in Arteriogenesis
- Role of Vitamin D Deficiency in Male Fertility
- Running Ourselves To Death: Does Long Distance Running Increase The Risk Of Venous Thromboembolism?
- Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
- Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy
- SAFETY AND EFFICACY OF LANREOTIDE DEPOT VS PLACEBO IN NEUROENDOCRINE TUMOR PATIENTS WITH A HISTORY OF CARCINOID SYNDROME AND PRIOR OCTREOTIDE THERAPY.
- SAFETY AND EFFICACY OF MCC-257 IN DIABETIC PERIPHERAL NEUROPATHY: RESULTS OF A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL AND OPEN-LABEL EXTENSION
- SAFETY AND EFFICACY OF WC2031 VS VIBRAMYCIN FOR THE TREATMENT OF UNCOMPLICATED UROGENITAL CHLAMYDIA TRACHOMATIS INFECTION
- Safety and efficacy results for the segesterone acetate ethinyl estradiol (SA/EE) contraceptive vaginal ring
- Safety and Tolerability of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women: Findings From a 1-Year, Randomized, Placebo- and Active-controlled, Phase 3 Trial
- Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
- Safety and Tolerability of Lanreotide Autogel/Depot in Patients With Neuroendocrine Tumors: Pooled Analysis of Clinical Studies
- SAFETY AND TOLERABILITY OF THE AGILE PATCH, A CONTRACEPTIVE PATCH WITH LOW-DOSE ETHINYL ESTRADIOL (EE) AND LEVONORGESTREL (LNG), VS. COMBINATION ORAL CONTRACEPTIVES (COCS) IN OBESE VS. NON-OBESE WOMEN
- Safety of Oral Ospemifene in Phase 2/3 Placebo-controlled Clinical Trials
- Salvage Surgery for Locoregional Failure after Chemoradiation in Rectal Squamous Cell Carcinoma: A National Cancer Database Analysis
- Salvage Therapy for Recurrent Gastrojejunal Anastomotic Stricture Using a Lumen-Apposing Metal Stent
- SATISFACTION WITH THE SEGESTERONE ACETATE AND ETHINYL ESTRADIOL CONTRACEPTIVE VAGINAL SYSTEM AMONG PREVIOUS ORAL CONTRACEPTIVE OR CONTRACEPTIVE VAGINAL RING USERS.
- Screening for major congenital heart defects in twin pregnancies between 11+0 and 13+6 weeks gestation
- Second Primary Lung Cancer Associated with Breast Conservation Therapy
- Secondary Malignancies in Patients with Bronchial, Pancreatic, Small Intestinal, and Rectal Neuroendocrine Tumors